Contineum Therapeutics, Inc. (CTNM) — Financial ratios
Profitability, liquidity, leverage, and valuation ratios for Contineum Therapeutics, Inc., with annual and quarterly history.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Valuation | |||||
| P/E Ratio | -5.28x | -8.96x | 17.03x | -15.96x | -13.34x |
| P/B Ratio | 1.21x | 1.91x | -5.70x | 9.86x | 6.28x |
| P/S Ratio | 0.00x | 0.00x | 7.74x | 0.00x | 0.00x |
| Profitability | |||||
| Gross Margin | 0.0% | 0.0% | 100.0% | 0.0% | 0.0% |
| Operating Margin | 0.0% | 0.0% | -32.2% | 0.0% | 0.0% |
| Net Margin | 0.0% | 0.0% | 45.4% | 0.0% | 0.0% |
| EBITDA Margin | 0.0% | 0.0% | 47.1% | 0.0% | 0.0% |
| Liquidity | |||||
| Current Ratio | 27.50x | 20.69x | 23.29x | 6.41x | 18.99x |
| Quick Ratio | 27.50x | 20.69x | 23.29x | 6.41x | 18.99x |
| Leverage | |||||
| Debt/Equity | 0.03x | 0.03x | -2.84x | 0.15x | 0.08x |
YoY = year-over-year change. Source: FMP..